These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
157 related items for PubMed ID: 7260907
1. Synergistic effects with inhibitors of de novo pyrimidine synthesis, acivicin, and N-(phosphonacetyl)-L-aspartic acid. Loh E, Kufe DW. Cancer Res; 1981 Sep; 41(9 Pt 1):3419-23. PubMed ID: 7260907 [Abstract] [Full Text] [Related]
2. Effects of acivicin and PALA, singly and in combination, on de novo pyrimidine biosynthesis. Kensler TW, Jayaram HN, Cooney DA. Adv Enzyme Regul; 1982 Sep; 20():57-73. PubMed ID: 7113804 [Abstract] [Full Text] [Related]
3. Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate. Moyer JD, Handschumacher RE. Cancer Res; 1979 Aug; 39(8):3089-94. PubMed ID: 455293 [No Abstract] [Full Text] [Related]
4. Kinetics of N-(phosphonacetyl)-L-aspartate and pyrazofurin depletion of pyrimidine ribonucleotide and deoxyribonucleotide pools and their relationship to nucleic acid synthesis in intact and permeabilized cells. Moyer JD, Smith PA, Levy EJ, Handschumacher RE. Cancer Res; 1982 Nov; 42(11):4525-31. PubMed ID: 7127293 [Abstract] [Full Text] [Related]
5. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin). Ardalan B, Jayaram HN, Johnson RK. Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405 [Abstract] [Full Text] [Related]
8. Therapeutic effects of acivicin and N-(phosphonacetyl)-L-aspartic acid in a biochemically designed trial against a N-(phosphonacetyl)-L-aspartic acid-resistant variant of the Lewis lung carcinoma. Kensler TW, Reck LJ, Cooney DA. Cancer Res; 1981 Mar; 41(3):905-9. PubMed ID: 7459876 [No Abstract] [Full Text] [Related]
9. Flux through the de novo pyrimidine pathway in vivo. Effect of N-phosphonacetyl-L-aspartate, a potent inhibitor of aspartate transcarbamylase. Monks A, Anderson LW, Strong J, Cysyk RL. J Biol Chem; 1983 Nov 25; 258(22):13564-9. PubMed ID: 6417130 [Abstract] [Full Text] [Related]
10. Effect of inhibitors of the de novo pyrimidine biosynthetic pathway on serum uridine levels in mice. Karle JM, Anderson LW, Dietrick DD, Cysyk RL. Cancer Res; 1981 Dec 25; 41(12 Pt 1):4952-5. PubMed ID: 6171344 [Abstract] [Full Text] [Related]
14. The glutamine analog acivicin as antipyrimidine. Studies on the interrelationship between pyrimidine and urea synthesis in liver. Pausch J, Rasenack J, Häussinger D, Holstege A, Gerok W. Adv Enzyme Regul; 1985 Jan 10; 24():233-43. PubMed ID: 3835821 [Abstract] [Full Text] [Related]
15. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid. Kensler TW, Mutter G, Hankerson JG, Reck LJ, Harley C, Han N, Ardalan B, Cysyk RL, Johnson RK, Jayaram HN, Cooney DA. Cancer Res; 1981 Mar 10; 41(3):894-904. PubMed ID: 7459875 [Abstract] [Full Text] [Related]